On September 15 2026 China’s startup funding news cycle delivered something that no single large round could have communicated alone. Four hardware and AI infrastructure companies disclosed more than RMB 500 million combined in a single 16-hour window. Every one of them is building something physical — robots, semiconductor inspection systems, sovereign AI infrastructure, drug discovery platforms. China’s AI moment in September 2026 is not a software story. It is a physical world story. Follow every China and Asia startup story at BestStartup Asia.
ENCOS Raises More Than RMB 300 Million. Building the Mechanical Backbone of Physical AI.
The largest round of September 15 from China came from ENCOS — a Nanjing-based robotics components company that raised more than RMB 300 million in a Series B. ENCOS builds the mechanical systems that go inside humanoid robots and embodied AI platforms — the actuators, joints, transmission systems, and structural components that allow a robot to move, grip, lift, and interact with the physical world.
This is the category that rarely makes startup headlines because it lacks the narrative clarity of a finished product. Nobody will film an ENCOS component going viral on social media. But every humanoid robot company in China — and there are dozens of them — needs what ENCOS builds. The company sits at the supply chain layer beneath the finished robot brands, which means its addressable market grows with every new humanoid robot company that enters the market, not just with ENCOS’s own commercial success.
The Series B signals that institutional investors have concluded that the humanoid robotics market is real enough to invest in the supply chain, not just the finished product. That is a maturity marker for the entire Chinese physical AI ecosystem. Read more China startup stories at BestStartup Asia.
Yincheng Intelligence Raises Nearly RMB 100 Million. Logistics Robots With Real Orders.
Shanghai-based Yincheng Intelligence raised nearly RMB 100 million after landing a major logistics robot order from a large customer. The sequencing matters — the order came first, then the raise. This is not a company raising capital on the strength of a demo or a pilot. It is a company that has demonstrated commercial demand at scale and is now raising capital to fulfil it.
Logistics robotics is one of the most competitive categories in Chinese AI hardware. Warehouse automation, autonomous mobile robots, and last-mile delivery systems are being deployed at massive scale by JD.com, Alibaba, Meituan, and dozens of third-party logistics operators across China. Yincheng’s ability to land a major logistics customer order before its institutional round is the clearest possible commercial validation signal. The RMB 100 million funds manufacturing scale-up to fulfil the order and additional customer acquisition.
Nutshell Therapeutics Raises Tens of Millions in C1 Round. AI Drug Discovery With Clinical Proof.
Shanghai-based Nutshell Therapeutics — also known as Yudao Bio — raised tens of millions of dollars in a C1 round co-led by Trustbridge Capital and Decheng Capital, with Dachen Caizhi and Zhongsheng Xichuang Dingqi Fund also participating. The company uses AI and physics-based modelling to attack drug targets that have historically been considered undruggable.
What separates Nutshell from most AI drug discovery companies is clinical progression. Its p53 Y220C candidate Dalretapopt is advancing through an international Phase I programme and moving toward Phase II. Another programme targeting NRF2 is planned for Phase I testing in both China and the United States. These are not computational predictions or preclinical results. These are drugs in human trials. In a field where AI drug discovery companies often raise significant capital on the strength of computational tools alone, Nutshell’s clinical data makes it a genuinely differentiated investment. Follow every Asia deep tech story at BestStartup Asia.
Japan’s Yoom Raises ¥700 Million. AI Workflow Automation for Japanese Enterprises.
Crossing from China to Japan, Yoom raised ¥700 million in its first institutional round from Dual Bridge Capital, Mizuho Capital, Shizuoka Capital, Harizury, and Canon Marketing Japan Future Investment Fund. The investor list is notable — Mizuho Capital is the corporate venture arm of one of Japan’s three largest banks, and Canon Marketing Japan’s investment fund represents one of Japan’s most established enterprise technology distributors backing a workflow automation startup.
Yoom builds AI-powered workflow automation for Japanese enterprises — connecting business applications, automating repetitive processes, and reducing the manual data entry and system-switching work that consumes significant productive time in Japanese business environments. The Japanese enterprise software market has historically lagged in automation adoption compared to US and European peers, but the combination of an ageing workforce, labour shortages, and government digital transformation mandates has created genuine urgency for workflow automation solutions tailored to Japanese business processes.
What China and Japan’s September 15 2026 Funding Tells the World
ENCOS, Yincheng, Nutshell, and Yoom represent four different categories but the same underlying conviction. Physical AI — robots, drug discovery, enterprise automation — is attracting institutional capital in China and Japan at a pace and scale that pure software AI never managed in these markets. The reason is specific to East Asian industrial structure. China and Japan are manufacturing-led economies where the commercial value of AI is most clearly expressed when it touches physical processes — production lines, logistics networks, drug development pipelines, enterprise workflows.
The September 15 cluster from China and Japan is not an anomaly. It is the latest data point in a consistent trend that has been building across Asia for 18 months. Follow every China, Japan, and Asia startup story at BestStartup Asia.
Key Takeaways
ENCOS raised more than RMB 300 million Series B on September 15 2026 for robotics mechanical components in Nanjing. Yincheng Intelligence raised nearly RMB 100 million in Shanghai after landing a major logistics robot order. Nutshell Therapeutics raised tens of millions in a C1 round for AI drug discovery with clinical trial progression on two candidates. Yoom raised ¥700 million from Mizuho Capital, Canon Marketing Japan Future Investment Fund, and others for AI workflow automation for Japanese enterprises. Four Chinese hardware and AI infrastructure companies disclosed more than RMB 500 million combined in 16 hours on September 15 2026. China’s AI moment is a physical world story not a software story. Japan’s enterprise AI adoption is accelerating driven by labour shortages and digital transformation mandates.
Frequently Asked Questions
What is ENCOS and why did it raise RMB 300 million?
ENCOS is a Nanjing-based robotics components company that raised more than RMB 300 million in a Series B on September 15 2026. It builds the mechanical systems inside humanoid robots — actuators, joints, and transmission components — sitting at the supply chain layer beneath finished robot brands. Its market grows with every new humanoid robot company that enters the market.
What is Nutshell Therapeutics and what makes its AI drug discovery different?
Nutshell Therapeutics is a Shanghai AI drug discovery company that uses AI and physics-based modelling to attack previously undruggable targets. Its p53 Y220C candidate Dalretapopt is in international Phase I trials advancing toward Phase II — actual human clinical data that distinguishes it from AI drug discovery companies with only computational predictions.
What is Yoom and why did Canon Marketing Japan invest?
Yoom is a Japanese startup building AI workflow automation for Japanese enterprises. Canon Marketing Japan Future Investment Fund’s participation alongside Mizuho Capital signals that established Japanese enterprise technology distributors see Yoom as a commercial partner, not just a financial investment.
Where can I follow China and Japan startup funding news?
Follow every China, Japan, and Asia startup funding story at BestStartup Asia — updated every week across every country in the region.
